Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and level ventricular hypertrophy:A Losartan Intervention for endpoint reduction (LIFE) substudy

Autor: Kjeldsen, S.E., Dahlöf, B., Devereus, R.B., Julius, S., Aurup, P., Edelman, J., Beevers, G., de Fair, U., Fyhrquist, F., Ibsen, H., Kristianson, K., Lederballe-Pedersen, O., Lindholm, L.H., Nieminen, M.S., Omvik, P., Oparis, S., Snapinn, S., Wedel, H.

Publikováno v: Kjeldsen, S E, Dahlöf, B, Devereus, R B, Julius, S, Aurup, P, Edelman, J, Beevers, G, de Fair, U, Fyhrquist, F, Ibsen, H, Kristianson, K, Lederballe-Pedersen, O, Lindholm, L H, Nieminen, M S, Omvik, P, Oparis, S, Snapinn, S & Wedel, H 2002, ' Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and level ventricular hypertrophy : A Losartan Intervention for endpoint reduction (LIFE) substudy ' J Am Med Assoc, vol. 288, pp. 1491-1498 .

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pure_au_____::d8a4837374a35cca7e549d2f2cf4ab20
https://pure.au.dk/portal/da/publications/effects-of-losartan-on-cardiovascular-morbidity-and-mortality-in-patients-with-isolated-systolic-hypertension-and-level-ventricular-hypertrophy(b869ecc0-b8d7-11da-bee9-02004c4f4f50).html